• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

    11/21/24 10:59:28 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMMB alert in real time by email
    SC 13G 1 CMMB13g.htm SCHEDULE 13G 13G Template
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (AMENDMENT N0. 1)


    Chemomab Therapeutics Ltd.

    (Name of Issuer)


    American Depository Shares, each of which represent twenty ordinary shares, no par value

    (Title of Class of Securities)


    16385C104

    (CUSIP Number)


    November 21, 2024

    (Date of Event Which Requires Filing of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         |_| Rule 13d-1(b)

         |X| Rule 13d-1(c)

         |_|Rule 13d-1(d)








    CUSIP NO. 16385C104

        1 Name Of Reporting Persons
      Erik Otto
       

        2 Check The Appropriate Box If A Member Of A
        Group (See Instructions)
    (a)  |_|
        (b)  |_|
         

        3 SEC Use Only
       

        4 Citizenship Or Place Of Organization
      Canada

        5 Sole Voting Power
    Number of   1,155,000

    Shares   6 Shared Voting Power
        0
    Beneficially    

    Owned By   7 Sole Dispositive Power
        1,155,000
    Each    

    Reporting   8 Shared Dispositive Power
    Person With   0

        9 Aggregate Amount Beneficially Owned By Each Reporting Person
      1,155,000

       10 Check If The Aggregate Amount In Row (9) Excludes Certain Shares
        

       11 Percent Of Class Represented By Amount In Row 9
      6.1%(*)

       12 Type Of Reporting Person (See Instructions)
      IN

    *Based on 18,856,611 ADSs outstanding as of November 14, 2024 (As provided by the Issuer)





    Item 1 (a). Name of Issuer:  Chemomab Therapeutics Ltd.
         
    Item 1 (b). Address of Issuer's Principal Executive Offices:
         
                                         Kiryat Atidum, Building 7
                                         Tel Aviv 6158002
                                         Israel
                        
         
    Item 2 (a). Name of Person Filing:  Erik Otto
         
    Item 2 (b). Address of Principal Business Office:   144 West Oakview Place, San Antonio, TX 78209
         
    Item 2 (c). Citizenship:  Canada
         
    Item 2 (d). Title of Class of Securities:  American Depository Shares, each of which represent twenty ordinary shares, no par value
         
    Item 2 (e). CUSIP Number:  16385C104
         

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      (a) |_| Broker or dealer registered under Section 15 of the Act.

      (b) |_| Bank as defined in Section 3(a)(6) of the Act.

      (c) |_| Insurance company as defined in Section 3(a)(19) of the Act.

      (d) |_| Investment company registered under Section 8 of the Investment Company Act.

      (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1) (ii)(E);

      (f) |_| An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

      (g) |_| A parent holding company, in accordance with Rule 13d-1(b)(ii)(G);

      (h) |_| A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

      (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

      (j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

    Item 4. Ownership.
         

      (a) Amount beneficially owned:  1,155,000
         
      (b) Percent of Class:  6.1%(*)
         
      (c) Number of shares as to which such person has:

      (i) Sole power to vote or to direct the vote:  1,155,000

    *Based on 18,856,611 ADSs outstanding as of November 14, 2024 (As provided by the Issuer)








      (ii) Shared power to vote or to direct the vote:  0
         
      (iii) Sole power to dispose or to direct the disposition of:  1,155,000
         
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of Five Percent or Less of a Class:   Not Applicable
         
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:  Not Applicable
         
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:  Not Applicable
         
    Item 8. Identification and Classification of Members of the Group:  Not Applicable
         
    Item 9. Notice of Dissolution of Group.
         
    Item 10. Certification.

            By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.

    SIGNATURE

            After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:   November 21, 2024

    /s/ Erik Otto                      
    Signature
    Get the next $CMMB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMMB

    DatePrice TargetRatingAnalyst
    5/13/2024$4.00Buy
    Maxim Group
    5/6/2024$6.00Perform → Outperform
    Oppenheimer
    12/19/2023$7.00Buy
    ROTH MKM
    3/10/2022$30.00 → $20.00Outperform
    Oppenheimer
    12/7/2021$30.00Buy
    Aegis Capital
    More analyst ratings

    $CMMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

      SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

      11/29/24 3:04:59 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

      SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

      11/21/24 10:59:28 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

      SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

      9/16/24 4:34:03 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Leadership Updates

    Live Leadership Updates

    See more
    • Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

      TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions. He will be responsible for spearheading the corpor

      11/30/22 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer

      TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development. "We believe Dr. Frankel's wealth of experience across all aspects of clinical development and medical affairs, along with his outstanding performance in helping to bring biologic and

      11/14/22 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

      ─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President  of Clinical Development─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. "Ch

      8/12/22 6:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Financials

    Live finance-specific insights

    See more
    • Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

      TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.                                                     

      10/30/24 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

      TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company

      8/12/24 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

      First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically Significant Improvements in Liver Stiffness, a Well-Validated Biomarker of Disease Progression in PSC Treatment with CM-101 Led to Statistically Significant Improvements in Pruritis and Improvements in Total Bilirubin and Liver Function Tests Positive Phase 2 Data Paves Way f

      7/25/24 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

      —New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041— —Further Expands Protections Provided by Nebokitug's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and Additional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections in China and Ru

      6/3/25 8:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      —Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis— —Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial— —These Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to Potentially Become the First FDA-Approved Treatment for PSC— —Cash Runway Extended to the Second Quarter of 2026— —Company Advancing Multiple Partnering Options for Executing the Nebokitug Program— TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIR

      5/15/25 8:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

      SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Progression Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 TEL AVIV, Israel and SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING

      5/5/25 8:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Darvish Nissim

      4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

      7/5/23 5:48:43 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Quigley Jill M.

      4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

      6/20/23 6:03:03 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fatal Sigal

      4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

      6/16/23 4:03:05 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    SEC Filings

    See more
    • SEC Form 6-K filed by Chemomab Therapeutics Ltd.

      6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

      5/27/25 4:05:25 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Chemomab Therapeutics Ltd.

      6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

      5/15/25 8:00:10 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Chemomab Therapeutics Ltd.

      6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

      4/15/25 8:00:43 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Chemomab Therapeutics with a new price target

      Maxim Group initiated coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $4.00

      5/13/24 8:28:18 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Chemomab Therapeutics from Perform to Outperform and set a new price target of $6.00

      5/6/24 7:45:06 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Chemomab Therapeutics with a new price target

      ROTH MKM resumed coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $7.00

      12/19/23 6:47:13 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care